GeneGo and Omicsoft Collaborate on Pathway Analysis for Next Generation Sequence Data
ST. JOSEPH, Mich., Sept. 29 /PRNewswire/ — GeneGo, Inc., the leading systems biology tools company and Omicsoft Corporation, the leader in the OMIC repository and analysis field, announced today integration of Omicsoft’s Next Generation Sequencing tools with GeneGo’s MetaCore data mining suite.
Array Studio, Omicsoft’s software package that provides state of the art statistics analysis and visualization tools for high dimensional quantification data (OMICS data), also supports analysis of Next Generation Sequencing Data (both RNA-Seq and DNA-Seq). Omicsoft has developed high performance proprietary sequence alignment algorithms for the major NGS platforms, i.e. Illumina’s Solexa, Roche’s 454 and SOLID from Life Technologies. Array Studio fully supports known and novel exon junction detection, fusion gene detection (both single end and paired end), expression value calculation, along with mutation reporting/annotation and more, all in one easy-to-use software package which provide complete analysis from machine-generated sequence runs to the lists of modified genes and polymorphisms.
Array Studio is seamlessly integrated with GeneGo’s data mining suites MetaCore and MetaDrug, allowing in depth analysis of the users NGS data.
“Omicsoft is delighted to continue its partnership with GeneGo, as the -OMICs field enters a new era with next generation sequencing technology. We feel that our alignment algorithm, coupled with our industry leading visualization and statistical package Array Studio, will allow us to continue to pave the way in the -OMICs industry. The extra benefits provided by NGS platforms, for instance, detection of gene fusion, will play a key role in biomarker discovery in cancer genomics. Integration with GeneGo’s platforms is key to this success, through their tools for systems biology,” said Jack Liu, President of Omicsoft.
“We are happy to extend our long-term collaboration with Omicsoft into next-generation sequencing,” said Julie Bryant, GeneGo’s VP of Business development. “NGS technologies provide the richest content data in life sciences, and we believe that they have one of the most comprehensive solutions. Pathway and network analysis is a natural next step for these complex data, and we are glad that we can provide our customers with a seamlessly integrated workflows from raw sequence data to biologically meaningful hypotheses on biomarkers, drug targets and drug repositioning.”
About GeneGo, Inc.
GeneGo, Inc. develops systems biology technology such as compound based pathway analysis, cheminformatics & bioinformatics software for life science research. The original computational MetaDiscovery(TM) platform allows an integration and expert analysis of different kinds of experimental data (mRNA expression, proteomics, metabolomics, microRNA assays and other phenotypic data) and relevant bioactive chemistry (metabolites, drugs, other xenobiotics) within the framework of curated biological pathways and networks. GeneGo’s flagship product, MetaCore 6.3(TM), assists pharmaceutical scientists in the areas of target selection and validation, data mining in biology, identification of biomarkers for disease states and toxicology. The second product, MetaDrug 6.3(TM) is designed for prediction of human metabolism, toxicity and biological effects for novel small molecules compounds. MetaBase(TM) represents the knowledge base for MetaCore.
For more information, please visit the company’s web site at www.genego.com.
SOURCE GeneGo, Inc.